|
Name |
alpha-Selinene
|
Molecular Formula | C15H24 | |
IUPAC Name* |
(3R,4aR,8aR)-5,8a-dimethyl-3-prop-1-en-2-yl-2,3,4,4a,7,8-hexahydro-1H-naphthalene
|
|
SMILES |
CC1=CCC[C@]2([C@H]1C[C@@H](CC2)C(=C)C)C
|
|
InChI |
InChI=1S/C15H24/c1-11(2)13-7-9-15(4)8-5-6-12(3)14(15)10-13/h6,13-14H,1,5,7-10H2,2-4H3/t13-,14+,15-/m1/s1
|
|
InChIKey |
OZQAPQSEYFAMCY-QLFBSQMISA-N
|
|
Synonyms |
ALPHA-SELINENE; 473-13-2; Eudesma-3,11-diene; alpha-Selinine; 99ZHA8F274; (2R-(2alpha,4aalpha,8abeta))-1,2,3,4,4a,5,6,8a-Octahydro-4a,8-dimethyl-2-(1-methylethenyl)naphthalene; (2R,4aR,8aR)-4a,8-dimethyl-2-(prop-1-en-2-yl)-1,2,3,4,4a,5,6,8a-octahydronaphthalene; (3R,4aR,8aR)-5,8a-dimethyl-3-prop-1-en-2-yl-2,3,4,4a,7,8-hexahydro-1H-naphthalene; 2-Isopropenyl-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalene; alpha-celinene; UNII-99ZHA8F274; SELINA-3,11-DIENE; (-)-.ALPHA.-SELINENE; CHEBI:59961; DTXSID50963792; .ALPHA.-SELINENE, (-)-; Naphthalene, 1,2,3,4,4a,5,6,8a-octahydro-4a,8-dimethyl-2-(1-methylethenyl)-, (2R-(2alpha,4aalpha,8abeta))-; XS174882; C22044; Q7448480; (2R-(2.ALPHA.,4A.ALPHA.,8A.BETA.))-1,2,3,4,4A,5,6,8A-OCTAHYDRO-4A,8-DIMETHYL-2-(1-METHYLETHENYL)NAPHTHALENE; NAPHTHALENE, 1,2,3,4,4A,5,6,8A-OCTAHYDRO-4A,8-DIMETHYL-2-(1-METHYLETHENYL)-, (2R,4AR,8AR)-
|
|
CAS | 473-13-2 | |
PubChem CID | 10856614 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 204.35 | ALogp: | 5.2 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.518 |
Caco-2 Permeability: | -4.536 | MDCK Permeability: | 0.00001790 |
Pgp-inhibitor: | 0.207 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.929 |
30% Bioavailability (F30%): | 0.943 |
Blood-Brain-Barrier Penetration (BBB): | 0.06 | Plasma Protein Binding (PPB): | 95.71% |
Volume Distribution (VD): | 2.375 | Fu: | 2.79% |
CYP1A2-inhibitor: | 0.527 | CYP1A2-substrate: | 0.538 |
CYP2C19-inhibitor: | 0.343 | CYP2C19-substrate: | 0.904 |
CYP2C9-inhibitor: | 0.216 | CYP2C9-substrate: | 0.461 |
CYP2D6-inhibitor: | 0.061 | CYP2D6-substrate: | 0.768 |
CYP3A4-inhibitor: | 0.47 | CYP3A4-substrate: | 0.301 |
Clearance (CL): | 11.037 | Half-life (T1/2): | 0.141 |
hERG Blockers: | 0.026 | Human Hepatotoxicity (H-HT): | 0.279 |
Drug-inuced Liver Injury (DILI): | 0.046 | AMES Toxicity: | 0.003 |
Rat Oral Acute Toxicity: | 0.016 | Maximum Recommended Daily Dose: | 0.235 |
Skin Sensitization: | 0.583 | Carcinogencity: | 0.138 |
Eye Corrosion: | 0.967 | Eye Irritation: | 0.978 |
Respiratory Toxicity: | 0.107 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001836 | 1.000 | D0B4RU | 0.235 | ||||
ENC001079 | 0.577 | D0A2AJ | 0.230 | ||||
ENC002990 | 0.439 | D04GJN | 0.225 | ||||
ENC001832 | 0.414 | D0I2SD | 0.225 | ||||
ENC002248 | 0.410 | D07BSQ | 0.221 | ||||
ENC005066 | 0.410 | D0F1UL | 0.221 | ||||
ENC002124 | 0.410 | D06AEO | 0.217 | ||||
ENC005497 | 0.410 | D0SC8F | 0.217 | ||||
ENC003367 | 0.403 | D07QKN | 0.217 | ||||
ENC003255 | 0.390 | D04SFH | 0.211 |